Erasca ERAS
NASDAQ ERAS
$16.17 -0.09 (-0.58%)
As of: Sep 4, 2026 · 12:48 PM EDT

Erasca (ERAS) EBIT (2020 - 2026)

Erasca's (ERAS) quarterly EBIT came in at -$187.9 million in Q1 2026, down 427.4% YoY from $57.4 million in Q1 2025, and down 476.34% on a QoQ basis from -$32.6 million in Q4 2025.

Analysis

Erasca (ERAS) EBIT (2020 - 2026) Analysis & Trends

Erasca (ERAS) has 7 years of EBIT data on file, last reported at -$187.9 million in Q1 2026.

  • Quarterly EBIT fell 427.4% year-over-year to -$187.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$293.2 million (down 66.24% YoY) and the FY2025 annual result came in at -$140.9 million, up 21.54% from the prior year.
  • EBIT slipped to -$187.9 million in Q1 2026, from -$32.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$32.6 million in Q4 2025 to a low of -$187.9 million in Q1 2026.
  • A 5-year average of -$52.8 million and a median of -$36.5 million in 2022 frame the typical range for EBIT.
  • Annual changes were most pronounced in 2023 — EBIT jumped 75.47% — and 2026, when it plunged 427.4%.
  • Tracing ERAS's EBIT over 5 years: stood at -$138.1 million in 2022, then jumped by 75.47% to -$33.9 million in 2023, then fell by 5.43% to -$35.7 million in 2024, then increased by 8.7% to -$32.6 million in 2025, then plunged by 476.34% to -$187.9 million in 2026.
  • The last three EBIT figures came in at -$187.9 million (Q1 2026), -$32.6 million (Q4 2025), and -$34.5 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT (Qtr)
1 Vertex Pharmaceuticals 139.76 Bn 131.91 Bn 2.84 Bn 1.25 Bn
2 Regeneron Pharmaceuticals 85.72 Bn 77.72 Bn 3.93 Bn 1.29 Bn
3 Argenx Se 63.56 Bn 58.38 Bn 1.37 Bn 493.00 Mn
4 Moderna 57.87 Bn 52.73 Bn 52.00 Mn -815.00 Mn
5 Revolution Medicines 44.06 Bn 44.06 Bn - -505.13 Mn
6 BeOne Medicines 40.08 Bn 34.98 Bn 1.53 Bn 325.05 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.20 Bn 992.69 Mn 231.44 Mn
8 Royalty Pharma 28.54 Bn 27.70 Bn - 133.12 Mn
9 Insmed 27.49 Bn 26.33 Bn 358.27 Mn -1.55 Mn
10 Erasca 5.03 Bn 5.03 Bn - -47.62 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -47.62 Mn
Mar 31, 2026 -187.91 Mn
Dec 31, 2025 -32.60 Mn
Sep 30, 2025 -34.55 Mn
Jun 30, 2025 -38.13 Mn
Mar 31, 2025 -35.63 Mn
Dec 31, 2024 -35.71 Mn
Sep 30, 2024 -37.24 Mn
Jun 30, 2024 -67.78 Mn
Mar 31, 2024 -38.85 Mn
Dec 31, 2023 -33.87 Mn
Sep 30, 2023 -34.66 Mn
Jun 30, 2023 -35.97 Mn
Mar 31, 2023 -37.03 Mn
Dec 31, 2022 -138.08 Mn
Sep 30, 2022 -36.96 Mn
Jun 30, 2022 -35.91 Mn
Mar 31, 2022 -36.51 Mn
Dec 31, 2021 -31.05 Mn
Sep 30, 2021 -46.04 Mn